stockportfolio.pro
Climb Bio Inc (CLYM)
Healthcare · Biotechnology · NasdaqGM
Climb Bio Inc revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-20.67M | $-47.48M | $-45.24M | $-35.12M | $-73.90M | $-59.85M |
| Net margin | — | — | — | — | — | — |
Source: Climb Bio Inc SEC filings (10-K).
Explore 6 years of Climb Bio Inc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track CLYM in your portfolio →
Climb Bio Inc financial history by metric
About Climb Bio Inc
Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases. It is also developing budoprutug which is in phase 2 clinical trials for the treatment of primary membranous nephropathy and immune thrombocytopenia; and Phase 1b clinical trial indicated for the systemic lupus erythematosus. In addition, the company is developing CLYM116, a preclinical stage anti A Proliferation-inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobin A nephropathy (IgAN) and other B-cell mediated diseases. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wellesley Hills, Massachusetts.
Climb Bio Inc — frequently asked questions
What is Climb Bio Inc's revenue?
Climb Bio Inc (CLYM) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Climb Bio Inc profitable?
No — CLYM reported a net loss of $-59.85M in fiscal 2025.
What is CLYM's P/E ratio?
Climb Bio Inc trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Climb Bio Inc have?
As of fiscal year 2025, CLYM carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Climb Bio Inc's market cap?
Climb Bio Inc (CLYM) has a market capitalization of about $614.43M, based on the latest data in our nightly-refreshed cache.
When does Climb Bio Inc's fiscal year end?
CLYM's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Climb Bio Inc's official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.